LINC02619

Across TCGA pan-cancer cohorts, LINC02619 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated LINC02619 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LINC02619 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC02619 expression acts as an unfavorable survival marker.

LIHC, LUSC, and THYM are the cancer types where LINC02619 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.467	0.784	<.001	57	view →
LUSC	OS	Tertile	II,III,IV	0.133	0.732	<.001	36	view →
THYM	DFS	Tertile	All	0.107	0.884	.001	18	view →
ESCA	DFS	Tertile	All	0.148	0.673	.040	18	view →
SKCM	DFS	Tertile	IV	0.016	0.454	<.001	18	view →
THCA	DFS	Tertile	II,III,IV	0.514	0.884	.009	18	view →
KIRC	DFS	Tertile	III,IV	0.534	0.652	.025	18	view →
PAAD	DFS	Tertile	II,III,IV	0.175	0.451	.036	9	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	9	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

LINC02619–LIHC (OS)

Open the LIHC breakdown →